New York, NY (August 8, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of Mogamulizumab-kpkc (Poteligeo) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after…
As novel treatments have increased survival rates and changed treatment paradigms for lymphoma, the need to better understand the side effects of these new treatments on patients has been magnified. Some types of lymphoma are now treated with continuous pill…
In conjunction with the Mantle Cell Lymphoma Scientific Workshop, the Lymphoma Research Foundation announced two MCL Therapeutic Studies Grants, awarded to Sandeep Dave, MD, MS of Duke University and Jianguo Tao, MD of H. Lee Moffitt Cancer Center. As…
New York, NY (June 13, 2018) –The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed…
The Lymphoma Research Foundation (LRF) is pleased to announce that scientific proceedings and priorities from LRF’s Adherence in Oral Therapies Scientific Meeting has been published in the prestigious scientific journal, The ASCO Post. As co-chairs of both of LRF’s scientific…
New York, NY (June 8, 2018) – The U.S. Food and Drug Administration (FDA) announced today it has approved the use of venetoclax (VENCLEXTA) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with…
LRF Continues its Support of Young Investigators Dedicated to Developing Minimally Toxic Patient Therapies and Lymphoma Cures New York, NY – June 1, 2018 – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted to funding innovative…
The Lymphoma Research Foundation (LRF) notes with great sadness the passing of Robert “Bob” Fischer, Director Emeritus of the Foundation Board of Directors. Bob was a central figure in the history of LRF dating back to his initial meeting with…
New York, NY – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services –…
New York, NY (May 1, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (KYMRIAH ®) for the treatment of large B-cell lymphoma after two or…